Article authored by David Levin, Vice President at Clinipace. Strategic relationships with CROs have typically been the exclusive domain of large biotechnology and pharmaceutical firms with multi-millions to spend on clinical trials
See original here:
Emerging Pharmas and CROs need each other
Related Posts:
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice